Fentanyl (Perioperative Analgesia)
Brand names: Sublimaze (IV), Durogesic (patch)
Fentanyl is a potent short-acting synthetic opioid used perioperatively for analgesia and to blunt the stress response at induction and during surgery.
Adult dose
Paediatric dose
Dose adjustments
In patients with renal impairment reduced dosing of fentanyl should be considered, and these patients should be observed carefully for signs of fentanyl toxicity.
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to the active substance, to any of the excipients, or to other opioids
- Respiratory depression, obstructive airways disease
- Concurrent administration with monoamine oxidase inhibitors or within 2 weeks of their discontinuation
Side effects
- Nausea (26.1%) and vomiting (18.6%) - very common
- Muscle rigidity, which may also involve the thoracic muscles (10.4%) - very common
- Hypotension (8.8%) and hypertension (8.8%); bradycardia (6.1%), tachycardia, arrhythmia
- Sedation (5.3%), dyskinesia, dizziness; postoperative confusion; delirium (not known)
- Respiratory: laryngospasm, bronchospasm, apnoea (uncommon); respiratory depression (not known); airway complication of anaesthesia
- Hypersensitivity including anaphylactic shock, anaphylactic reaction and urticaria; drug dependence and drug withdrawal syndrome
Interactions
- Monoamine oxidase inhibitors - concurrent administration, or administration within 2 weeks of their discontinuation, is contraindicated (SPC section 4.3)
- CYP3A4 inhibitors (e.g. macrolide antibiotics such as erythromycin, azole antifungals such as ketoconazole, protease inhibitors) - can increase fentanyl plasma concentration causing increased or prolonged opioid effects; consider dose reduction and monitor frequently for respiratory depression and sedation (US FDA label; UK SPC section 4.5 was not in the fetched bundle)
- Chemically incompatible in solution with pentobarbital sodium, thiopentone and methohexitone (SPC section 6.2)
Clinical monograph
How it works
It is a strong mu-opioid receptor agonist, producing rapid-onset analgesia and dose-dependent respiratory depression.
Prescribing in practice
- It causes dose-dependent respiratory depression that may outlast its analgesic effect and can recur, so titrate carefully, ensure airway and ventilatory support, and have naloxone available.
- Rapid or high-dose administration can cause bradycardia and chest-wall (truncal) rigidity impairing ventilation.
- Effects are potentiated by other CNS depressants and benzodiazepines, increasing the risk of profound sedation.
Monitoring
Monitor respiratory rate, oxygen saturation, sedation level and haemodynamics during and after administration.
Counselling the patient
- You may feel very drowsy and your breathing will be monitored closely.
- Report any breathing difficulty or excessive sleepiness in recovery.
Evidence & guidelines
Perioperative use is established through its licensed anaesthetic indications and long-standing clinical practice.
Reference: RCoA Acute Pain Handbook; ANZCA Opioid Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- ASA Physical Status Classification · Pre-operative Risk
- Morphine Milligram Equivalents (MME) Calculator · Pain / Opioids
- Opioid Conversion / Equianalgesic Guide · Pain Management
- Numeric Rating Scale (NRS) for Pain · Pain Assessment
- POSSUM Score for Surgical Morbidity and Mortality · Perioperative Risk
- SORT (Surgical Outcome Risk Tool) · Perioperative Risk
- Major Trauma — Primary Survey (ATLS) · ATLS 10th Edition; JRCALC; NICE NG39
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Burns — TBSA Estimation & Fluid Resuscitation · British Burn Association; EMSB; RCEM 2024
- Lower Gastrointestinal Bleed · NICE; BSG; ACPGBI — Commissioning Guide
- Acute Pancreatitis · NICE; IAP/APA; ACPGBI — CG104
- Hypertrophic Pyloric Stenosis · BAPS / RCPCH